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T h et u m o rs u p p r e s s o rg e n eT P 5 3i sf r e q u e n t l ym u t a t e di nh u m a nc a n c e r s .A b n o r m a l i t yo ft h eT P 5 3g e n ei so n eo ft h em o s t
signiﬁcant events in lung cancers and plays an important role in the tumorigenesis of lung epithelial cells. Human lung cancers
are classiﬁed into two major types, small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). The latter accounts
for approximately 80% of all primary lung cancers, and the incidence of NSCLC is increasing yearly. Most clinical studies suggest
that NSCLC with TP53 alterations carries a worse prognosis and may be relatively more resistant to chemotherapy and radiation.
A deep understanding of the role of TP53 in lung carcinogenesis may lead to a more reasonably targeted clinical approach, which
should be exploited to enhance the survival rates of patients with lung cancer. This paper will focus on the role of TP53 in the
molecular pathogenesis, epidemiology, and therapeutic strategies of TP53 mutation in NSCLC.
1.Introduction
The TP53 gene, ﬁrst described in 1979, was the ﬁrst tumor
suppressor gene to be identiﬁed [1–4]. It was originally
believed to be an oncogene, but genetic and functional
data obtained 10 years after its discovery proved it to be
a tumor suppressor. Inactivation of TP53 function or its
attendant pathway is a common feature of human tumors
that often correlates with increased malignancy, poor patient
survival, and resistance to treatment [5–7]. The TP53 tumor
suppressor gene is located at the short arm of chromosome
17 (17p13). It contains 11 exons spanning 20 kilobases
and encodes a nuclear phosphoprotein of 53kDa. The
TP53 protein contains distinct functional domains: the
N-terminus transactivation domain, the sequence-speciﬁc
DNA-binding domain, the oligomerization domain, and the
C-terminus negative regulatory domain [8]. The TP53 gene
has been implicated in a growing number of biological
processes, including DNA repair, cell-cycle arrest, apoptosis,
autophagy,senescence,metabolism, andaging[6,9–11].The
transcription factor TP53 can activate the transcription of
numerous downstream genes, such as p21 and MDM2, by
binding to speciﬁc sequences, which often mediates their
biologicalfunctions[9,12,13].Indeed,theactivitiesofTP53,
both transcription dependent and independent, are regu-
lated via its mRNA and protein levels, cellular localization,
and ability to bind over 100 cellular proteins and control
the expression of thousands of potential target genes. Under
normal conditions, TP53 is rapidly degraded and, thus, not
present at detectable levels within the cell. Various types of
cellular stress, such as DNA damage induced by UV and
oncogeneactivation, result in thestabilization and activation
of TP53, causing protein accumulation within the nucleus.
The TP53 pathway is activated by such cellular stresses
that alter the normal cell-cycle progression or can induce
mutations of the genome, leading to the transformation of
a normal cell into a cancerous cell.
Lung cancer, primarily caused by tobacco exposure, is
one of the commonest neoplasms all over the world, with
approximately 1.35 million new cases worldwide in 2002
[14]. It is the leading cause of cancer death in the world,
with more than 1.18 million deaths in 2002 [14]. Despite
recent advances in surgical and chemo/radiation therapies,
the prognosis is very poor, with an overall survival rate
of only 15%. NSCLC represents a heterogeneous group
of cancers, consisting mainly of squamous cell carcinoma,2 Journal of Biomedicine and Biotechnology
adenocarcinoma, and large-cell carcinoma. Approximately
80% of human lung cancers are NSCLC, and their devel-
opment involves multiple genetic abnormalities that lead
to malignant transformation of the bronchial epithelial
cells, followed by invasion and lymph node and distant
metastases. Among such genetic abnormalities, the TP53
tumor suppressor gene appears to be the most frequent
target, and abnormality of TP53 plays an important role in
the tumorigenesis of lung epithelial cells. Indeed, mutations
of the TP53 gene occur in about 50% of NSCLC [15, 16].
As TP53 mutants are present in almost half of NSCLC
whose incidence rate increasing every year, the possibility of
abolishing their oncogenic eﬀects is undoubtedly important
for a successful treatment of NSCLC.
2.TP53Gene MutationsinHumanCancers
Mutations in the tumor suppressor TP53 gene are one of the
most common genetic alterations present at high frequency
in human cancers [6, 17–20]. Up to 50% of all human
cancers contain mutations in both alleles of the TP53 gene
[21–23]. Unlike most other tumor suppressor genes, such
a sR B ,A P C ,a n dB R C A 1g e n e s ,t h e ya r ei n a c t i v a t e db y
frameshift or nonsense mutations leading to disappearance
or aberrant synthesis of the gene product, almost 80% of
TP53 gene mutations are missense mutations [24]. Other
alterations include frameshift insertions and deletions (9%),
nonsense mutations (7%), silent mutations (5%), and other
infrequent alterations [25]. In 1991, a database of published
TP53 mutations was established by Dr. Curtis Harris and
his collaborators to facilitate the retrieval and analysis of
TP53 mutations [26]. Since 1994, this database has been
maintained at the International Agency for Research on
Cancer (IARC) [27] and is made freely available as a service
to the scientiﬁc community (http://www.iarc.fr/p53). The
current release is version R14 (November, 2009). It contains
26,597somaticmutationsand535germlineTP53mutations.
Germline TP53 mutation causes predisposition to early-
onset diversemesenchymal andepithelialneoplasms, includ-
ing breast carcinomas, sarcomas, brain tumors, and adrenal
cortical carcinomas, deﬁning the Li-Fraumenni syndrome,
which is a rare autosomal dominant syndrome [28–30].
As reported, somatic TP53 missense mutations are found
in approximately 50% of human cancers, and inactivating
mutations in the TP53 gene are the most common genetic
events in human cancers aﬀecting a speciﬁc gene, with the
vastmajority arising from asingle-point mutationin theseg-
ment encoding the DNA-binding domain of TP53 [21, 23].
The inactivating mutations render the mutant TP53 protein
unable to carry out its normal functions, that is, tran-
scriptional transactivation of downstream target genes that
regulate cell cycle and apoptosis [31]. Several recent lines of
evidence indicate that in addition to abrogating the tumor
suppressor functions of wild-type TP53, the common types
of cancer-associated TP53 mutations also endow the mutant
protein with new activities, so-called “gain-of-function”
(GOF) activities, which can contribute actively to various
stages of tumor progression, including distant metastases,
and to increased resistance to anticancer treatments. GOF
activities of mutant TP53 are exerted by aberrant protein
interaction or gene regulation, such as MAPKK3, inhibitor
of DNA-binding 4 (ID4), polo-like kinase 2 (Plk2), promye-
locytic leukemia protein (PML), and prolyl isomerase Pin1
(see Figure 1)[ 32–38]. Although the occurrence of TP53
mutations is not limited to a few particular sequences
or codons along this gene, most mutations cluster in the
TP53 DNA-binding domain, which encompasses exons ﬁve
through eight and spans approximately 180 codons or 540
nucleotides [39]. Most TP53 missense mutations lead to
the synthesis of a stable protein, which lacks its speciﬁc
DNA-binding and transactivation function and accumulates
in the nucleus of cells. These mutant accumulated pro-
teins are retained in distant metastasis. In addition, the
most frequent mutants have been shown to be capable of
cooperating with oncogenesforcellulartransformation [40].
About 30% of TP53 missense mutations found in cancer
correspond to nucleotide substitutions at highly mutable
CpG dinucleotides and at codons encoding residues that
play essential structural and chemical roles in the contact
between the TP53 protein and speciﬁc DNA sequences that
constitutetheTP53response elements[41].These mutations
result in a signiﬁcant loss of DNA-binding activity and
transactivation capacity [31]. It is noteworthy that ﬁve of
the six most prominent mutation hotspots in the TP53 gene
are represented by G to T mutations at codons containing
methylated CpG sequences, including codons 157, 158, 245,
248, and 273 [42]. The understanding of the tumor-speciﬁc
mutational spectra of the TP53 gene is quite important
for the realization of TP53-associated carcinogenesis [39].
Analysis ofthespectrum ofTP53mutationsinhumancancer
demonstrates a link between exposure to various types of
carcinogens and the development of speciﬁc cancers [43].
For example, tobacco smoke carcinogens are linked to G
to T mutations in lung cancer arising in smokers, as will
hereinafter be described in detail [44].
3.TP53 MutationsinNSCLC
3.1. TP53 Alterations in Lung Cancer. The frequent detection
of loss of heterozygosity (LOH) in lung cancer cell lines
and tumor samples at the location of the TP53 gene on
chromosome 17p13 suggested that this gene was likely to
be involved in the pathogenesis of lung cancer, and genetic
abnormality of the TP53 in lung cancers has been shown to
be associated with a poorer survival prognosis and increased
cellular resistance to therapy [45–47]. The highest frequency
of TP53 alterations is found in SCLC specimens [48–51].
On the other hand, the frequency of TP53 mutations is the
highest in squamous cell carcinomas and lower in adenocar-
cinomas among NSCLC tumor samples [52, 53]. It has been
reported that somatic mutations and increased expression of
TP53 were frequently found in ∼23% and ∼65% of NSCLC,
respectively, [54, 55]. TP53 mutations are found in tumors
both with and without allele loss at 17p13 and are mostly
located within the DNA-binding domain of TP53 [56].
Because coding mutations of TP53 occur relatively early inJournal of Biomedicine and Biotechnology 3
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Figure 1: A synthetic view of the p53 pathway. Mutant p53 exerts new oncogenic activities, so-called “gain-of-function” (GOF) activities,
which can contribute actively to various stages of tumor progression, including distant metastases, and to increased resistance to anticancer
treatments.
the development of lung cancer and are potentially required
for maintaining the malignant phenotype, the acquired
TP53 mutations are preserved during tumor progression
and metastatic spread [57, 58]. Chang et al. reported that
the incidence of TP53 mutations in primary tumors and
metastatic lymph nodes was 23.2% and 21.4%, respectively,
and the TP53 gene status in primary tumors and metastatic
lymph nodes showed 92.9% concordance among 56 patients
with NSCLC who had undergone surgical resection, which
explained the fact that TP53 mutations usually precede
lymph node metastasis [59]. Most TP53 mutations occur
before the tumor metastasizes. They are then preserved
through subsequent stages of tumor development; as a
result, no selection against TP53 mutations occurs during
metastasis.
3.2. Prognosis of NSCLC Patients in Wild-Type TP53 and
Mutant TP53. TP53 is the most extensively investigated
prognostic marker in NSCLC, and the following meta-
analyseshavesuggestedaweaktomodestnegativeprognostic
role for TP53. Steels et al. identiﬁed aberrant TP53 as a prog-
nostic factor in NCSCL at any stage (localized or advanced
disease) and any histology (adenocarcinoma and squamous
cell carcinoma). Moreover, no signiﬁcant diﬀerences were
found when comparing the diﬀerent antibodies used in
the Immunohistochemical (IHC) assays [47]. Mitsudomi
et al. analyzed protein overexpression and DNA mutations
separately. In lung cancer, the concordance between the
two assays in 60%–70% aberrant TP53 was globally more
prevalent in squamous cell carcinomas than in adenocar-
cinomas; however, its role as a prognostic marker was
signiﬁcant only in patients with this latter lung cancer type.
In conclusion, the presence of an aberrant TP53 status could
identify a disease with more aggressive features and, thus,
a potentially shorter survival [60]. Cancer and Leukemia
GroupB(CALGB)9633wasaphaseIIItrial thatrandomized
patients with stage IB NSCLC to either observation or
four cycles of carboplatin and paclitaxel. A statistically
signiﬁcant eﬀect in favor of adjuvant chemotherapy was seen
for disease-free survival (DFS) and overall survival (OS)
in the subgroup of patients with tumors ≥4cm. Recently ,
a laboratory companion study was conducted to deter-
mine whether molecular and clinical factors could provide
additional prognostic information. Formalin-ﬁxed, paraﬃn-
embedded blocks were obtained for 250 of the 344 patients
enrolled. IHC staining for TP53, bcl-2, blood group antigen
A ,a n dm u c i nw a sc o r r e l a t e dw i t hD F Sa n dO S .T h er e s u l t s
showed that the prevalence of TP53 and mucin expression
was 47% and 45%, respectively. Univariate analysis for DFS
showed a statistically signiﬁcant eﬀe c tf o rt h ep r e s e n c eo f
mucin (P = .0005) and TP53 (P = .05). In the multivariate
Cox model, there was a statistically signiﬁcant association
between shorter DFS and the presence of mucin (P = .002;
HR2.05)and TP53 (P = .003;HR1.95)and between shorter
OS and the presence of mucin (P = .004; HR 2.03) and4 Journal of Biomedicine and Biotechnology
TP53 (P = .0005; HR 2.30) [61]. In another published
study, TP53 protein expression was evaluated by IHC in
tissue samples of 253 completely resected NSCLC patients.
The incidence of TP53 protein overexpression was 52% (132
patients). Untreated TP53-positive patients had signiﬁcantly
shorter overall survival than patients with TP53-negative
tumors (P = .03; HR 1.89; 95% CI, 1.07–3.34). However,
these TP53-positive patients also had a signiﬁcantly greater
survival beneﬁt from adjuvant chemotherapy (P = .02;
HR 0.54) than patients with TP53-negative tumors (P =
.26; interaction P = .02; HR 1.40), indicating that TP53
protein overexpression is a signiﬁcant marker of poor
prognosis as well as a signiﬁcant predictive marker for
ad i ﬀerentially greater beneﬁt from adjuvant chemother-
apy in completely resected NSCLC patients [62, 63].
In addition, 35 patients with advanced NSCLC who had
received neoadjuvant chemotherapy in the context of a
prospective phase II trial were analyzed for the TP53
genotype of their tumors. Response to induction therapy
was then correlated to the TP53 genotype as assessed by
complete direct DNA sequencing. Patients had received 3
cycles of cisplatin and etoposide and 1 cycle of simulta-
neous radiochemotherapy. The presence of a mutant TP53
genotype was highly indicative of resistance to induction
chemotherapy (P<. 002). The sensitivity of the mutant
TP53 genotype to identify nonresponders was 94% (71.3–
99.9 conﬁdence interval). A normal TP53 gene was signif-
icantly associated with radical resection (P<. 004) and
survival advantage (P = .02) [64]. Thus, most of the
evidence indicates that alterations in TP53 are associated
with a poor prognosis. Nevertheless, there is no deﬁnitive
evidence that the knowledge of TP53 status could play
a role in the management of individual patients with
NSCLC.
3.3. TP53 Mutations in Tobacco-Associated Lung Cancer. As
already reported, human NSCLC is classiﬁed into several
subtypes. The incidence of the diﬀerent subtypes in NSCLC
haschanged overthelast twodecades.Sincetheintroduction
of ﬁltered tobaccocigarettes and the reduction in the number
of smokers, the percentage of individuals with adenocarci-
noma has increased whereas the incidence of squamous cell
carcinoma has decreased. Recentestimates indicate that 15%
of men and 53% of women with lung cancer worldwide are
never-smokers [14]. Otherwise, the leading risk factor for
lungcancerisundoubtedlytobaccosmoking, andtherisk for
lung cancer increases with the number of cigarettes smoked
and the duration of smoking [65, 66]. Tobacco smoking
accountsfor more than 90% oflungcancersin men and 74%
to 80% of lung cancers in women in the United States and
the European Union [14, 67–70]. Accordingto the prevailing
research, it is the direct mutagenic action on DNA the means
by which smoking causes lung cancer [71]. Because TP53
mutations are found in more than half of lung tumors, the
TP53 gene should be considered to be one of the most
frequenttargetsoftobaccosmoking-related DNAmutations.
In fact, TP53 mutations are the most extensively studied
mutations in lung cancer, and a database of all published
mutationsismaintained mainlybytheIARC,as notedabove.
Another database is curated by Dr. Therry Soussi, Curie
Institute, Paris, France (http://p53.curie.fr/). Patients with
tobacco-associated cancer have a higher frequency (26%–
71%) of TP53 mutations than patients who never smoked
(8%–47%) [72–74]. Until now, several studies have detected
hotspots on the TP53 gene, with G:C to T:A (G to T)
transversions being a characteristic ﬁnding in tobacco-
associated lung cancer [44, 58, 74, 75]. Ninety percent of the
guaninesundergoingthesetransversioneventsinlungcancer
are located on the nontranscribed DNA strand [42, 76].
Mutational hotspots within the Tp53 gene, for example,
codon 157, have been identiﬁed for tobacco-related lung
cancer whereas these same mutations are rarely found in
other cancers. The incidence for G to T transversions in
lung cancer tissues from never-smokers is signiﬁcantly lower
than that in those from smokers. The ratio of G to T
transversions to G:C to A:T (G to A) transversions was
1 . 0i ns m o k e r sa n d0 . 3 4i nn e v e r - s m o k e r s[ 77]. Another
study reported that a screening of 623 genes in 188 lung
adenocarcinomas conﬁrmed the higher mutation load and
higher fraction of strand-biased G to T transversions in lung
tumor of smokers when compared with nonsmokers [78].
The spectrum of G to T transversions is presumably induced
by polycyclic aromatic hydrocarbons (PAH) from tobacco
smoke. Benzo[α]pyrene is the most studied member of the
PAH class, and Benzo[α]pyrene diol epoxide (BPDE) is the
main metabolite of Benzo[α]pyrene, one of the most potent
carcinogens present in high quantity in tobacco smoke. The
BPDE-DNA adduct patterns in the TP53 gene in bronchial
epithelial cells coincide with G to T mutational hotspots
within codons 157, 248, and 273 in tobacco smoking-
associated lung cancers [79, 80]. G to T transversions are
typical for bulky adduct-producing mutagens, including
the class of PAHs, and BPDE adducts at these codons
[81].
3.4. TP53 Mutational Spectra between Never-Smokers and
Smokers. Several epidemiological studies have identiﬁed
lung cancer in people who have never smoked as a distinct
entity from tobacco-associated lung cancer, and genetic
mutations are regarded to be more common in patients with
tobacco-associated lung cancer than in never-smokers. Lung
cancerfromsmokersshowsadistinct,uniqueTP53mutation
spectrum, such as G to T transversions at codons 157, 158,
179, 248, and 273, which is uncommonly observed in lung
cancer from nonsmokers [74, 75, 82]. Indeed, in smokers,
43% of the mutations were G to T transversions, but this
number dropped to 13% in never-smokers [78]. Another
analysis reported that the diﬀerence of the TP53 mutational
spectra between never-smokers and smokers was detectable
only in women [77]. The TP53 mutations in female never-
smokers with adenocarcinoma were predominantly transi-
tions (83%). However, in smokers, the TP53 mutations were
predominantly transversions (60%) and deletions (20%)
[83]. These ﬁndings suggest that the TP53 mutations in lung
cancer in never-smokers are distinct from those in tobacco-
associated lung cancer. In patients with adenocarcinoma,Journal of Biomedicine and Biotechnology 5
thefrequency ofTP53 mutations correlated with the amount
of tobacco smoked [84]. On the other hand, patients with
adenocarcinoma who have never smoked are more likely
to have mutations in the epidermal growth factor receptor
(EGFR) tyrosine kinase and have a better response to its
inhibitors than do patients with tobacco-associated lung
cancer [85]. It has been noticed that TP53 mutations are
closely related to smokers whereas EGFR mutations are
statistically signiﬁcantly more frequent in females and never-
smokers in adenocarcinoma [48, 86]. Furthermore, the
prevalenceofmutationsink-ras andTP53diﬀersforpatients
with lung cancer who neversmoked and those with tobacco-
associated lung cancer.
4.TherapeuticStrategiesforNSCLCwith
TP53Mutation
Several studies indicate that TP53 mutations confer
chemoresistance to lung cancer cells in vivo and in vitro
[87–90]. Determining TP53 status may be of great value
in the choice of chemo/radiation therapy. For instance, it
is well known that tumors containing the mutant TP53
are more resistant to ionizing radiation than those with
the wild-type TP53. The frequent inactivation of TP53 in
human tumors suggests that the reconstruction of the TP53
mediated pathway in tumor cells might be an attractive
tumor cell-speciﬁc strategy for treating cancers. One of
the most advanced strategies for therapeutic targeting of
the TP53 pathway in cancer is virus-based therapeutic
strategies for mutant TP53-carrying tumors. Wild-type
TP53 reconstitution in mutant TP53-carrying or TP53-null
tumors can be accomplished by gene therapy, that is, the
introductionofanintact cDNAcopybased onanadenovirus
(Adp53). Because of the frequent mutation in TP53 in lung
cancer, concomitant treatment with diﬀerent classes of
chemotherapy and TP53 gene replacement strategies has
been tested in preclinical as well as in clinical settings [91].
In preclinical studies with lung cancer cell lines expressing
mutated TP53, the TP53 replacement strategy has improved
chemotherapy and radiotherapy responses [92, 93]. TP53
gene therapy has also been tested in clinical trials in patients
withlungcancer,andsomeclinicalstudieshaveinfactshown
a beneﬁcial eﬀect of the combination of Adp53 gene therapy
and chemotherapeutic drugs and radiotherapy (reviewed
in [94]). In a phase I clinical trial, 28 patients with NSCLC
whose cancers had progressed on conventional treatments
were administered the Adp53 gene into the tumors without
any other therapies. Therapeutic activity in 25 evaluable
patients included signiﬁcant reduction in tumor size in
two patients (8%) and disease stabilization in 16 patients
(64%); the remaining seven patients (28%) exhibited disease
progression [95]. In another trial, Adp53 was administered
by bronchoscopic intratumoral injection in 12 patients
with advanced endobronchial NSCLC; six of the 12 (50%)
patients had signiﬁcant improvement in airway obstruction,
and 3 patients met the criteria for partial response [96].
Twenty-four patients with advanced NSCLC and abnormal
TP53 function received a total of 83 intratumoral injections
with Adp53with the administration of intravenous cisplatin.
As a result, 17 (71%) patients achieved the best clinical
response of stable disease, two patients achieved a partial
response, four patients had progressive disease, and one
patient was not assessable [97]. Nineteen patients with
NSCLC were treated with concurrent injection at the tumor
site of Adp53 and curative thoracic radiotherapy (60Gy) in
a clinical trial. Three months after completion of therapy,
pathologic biopsies of the primary tumor revealed no
viable tumor in 12 patients (63%), viable tumors in three
patients (16%), and no assessment in four patients (21%).
Computed tomography and bronchoscopic ﬁndings at the
primary injected tumor revealed complete response in one
patient (5%), partial response in 11 patients (58%), stable
disease in three patients (16%), progressive disease in two
patients (11%), and no evaluation in two patients (11%)
[98]. As reported, reconstitution of the disorganized TP53
tumor suppressor pathway, such as the introduction of
Adp53 into tumor cells, is one of the most promising novel
concepts for improved cancer therapy as just described.
More recently, several approaches for the identiﬁcation of
small molecules that target mutant TP53 have been applied,
includingrational designand screening ofchemical libraries.
RITA was originally identiﬁed in screening of the diversity
set from the National Cancer Institute (NCI) for drugs
able to suppress cell proliferation in a wild-type TP53-
dependent manner. Upon binding to TP53, RITA reactivates
it and induces apoptosis by disrupting the interaction
with HDM-2 [99]. Therefore, RITA was proposed as a key
molecule to target wild-type TP53 tumors that may prove
resistant to drugs that rescue mutant TP53 function, such
as PRIMA-1 (p53 reactivation and induction of massive
apoptosis) [100]. Zhao et al. showed that the response
elicited by RITA is dependent on the presence of mutant
TP53 and that it is sustained by reactivation of the apoptotic
machinery. They concluded that RITA is a promising lead
for the development of anticancer drugs that reactivate
the tumor suppressor function of TP53 in cancer cells,
irrespective of whether they express the mutant or wild-type
TP53 [101]. The compound PRIMA-1 has been identiﬁed
as a low-molecular-weight compound that selectively
inhibits the growth of tumor cells expressing mutant TP53.
PRIMA-1 restores wild-type conformation to mutant TP53
by binding to the core and induces apoptosis in human
tumor cells [102]. Furthermore, PRIMA-1MET/APR-246, a
methylated structural analog of the compound PRIMA-1
that was identiﬁed by screening of a chemical library, can
function synergistically with cisplatin or other commonly
used anticancer drugs to induce tumor cell apoptosis and
inhibition of human tumor xenograft growth in vivo in
SCID mice [103]. Another study showed that PRIMA-1
alone did not trigger apoptosis but signiﬁcantly reduced cell
viability in human NSCLC cell lines carrying diﬀerent TP53
proteins: A549 (p53wt), LX1 (p53R273H), and SKMes1
(p53R280K). In combination with adriamycin, PRIMA-1
strengthens the adriamycin-induced apoptosis in A549 and
LX1 [104]. Adp53 gene therapy, as well as small molecules,
such as PRIMA-1 and PRIMA-1MET,w h i c hc a nr e s t o r et h e
transcriptional function of mutant TP53, or RITA, which6 Journal of Biomedicine and Biotechnology
interferes with MDM2-directed TP53 degradation, has been
tested in a preclinical setting, and some of these approaches
are currently in clinical development. Furthermore, novel
TP53-based therapeutic strategies for NSCLC may be
combined with conventional and molecular-targeting cancer
therapy, including EGFR-TKI. The study of the somatic
genetics of the TP53 pathway in cancer cells and tumors has
proven useful in the development of targeted therapies and
has shown that the TP53 mutational status can serve as an
independent prognostic indicator in some types of cancers
[105, 106].
5.Summary
Asthe molecularbasis oflung carcinogenesis mustbe under-
stood more fully and exploited to enhance survival rates of
patients diagnosed with lung cancer, a deeper understanding
of the major molecular alterations that occur in lung cancer,
including TP53 gene mutation, is needed.
As a genetic alteration in the TP53 pathway is a common
denominator toall cancers, an understanding ofTP53 tumor
suppressor activity has great potential for the development
of novel therapeutic treatments of lung cancer. The use of
a TP53 gene therapy for cancer cells will be improved with
virusesthattargetonlycancercellsormoreeﬃcientmethods
of gene delivery exclusively to the cancer cells.
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